New hope for lung patients: Long-Term safety trial of inhaled therapy begins
NCT ID NCT07234032
First seen Nov 18, 2025 · Last updated May 10, 2026 · Updated 22 times
Summary
This study looks at the long-term safety of an inhaled drug called treprostinil palmitil (TPIP) for people with pulmonary hypertension linked to interstitial lung disease. About 344 adults who finished a previous study will take the drug and be monitored for side effects and breathing changes. The goal is to see if the drug remains safe and tolerable over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.